Bionomics set to enter Alzheimer's fray with new candidates
This article was originally published in Scrip
Executive Summary
Bionomics is planning to expand its pipeline with the selection of a drug candidate later this year for a new development programme in neurology expected to focus initially on Alzheimer's disease.